IQVIA Holdings Inc. (NYSE:IQV) Receives $241.88 Consensus Price Target from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $241.8824.

A number of brokerages have issued reports on IQV. JPMorgan Chase & Co. boosted their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Stifel Nicolaus boosted their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Mizuho raised their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th.

IQVIA Trading Up 0.8%

Shares of IQVIA stock opened at $261.57 on Monday. The stock has a 50 day moving average of $218.41 and a 200 day moving average of $188.59. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $262.51.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its position in IQVIA by 18,735.4% in the 2nd quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock valued at $9,514,450,000 after purchasing an additional 48,980,106 shares during the last quarter. BlackRock Inc. purchased a new position in IQVIA during the 2nd quarter worth $2,811,292,000. Boston Partners acquired a new position in IQVIA in the third quarter valued at $676,698,000. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter valued at about $497,445,000. Finally, Victory Capital Management Inc. boosted its stake in shares of IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after buying an additional 1,614,063 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.